Effect of Low Molecular Weight heparin versus warfarin sodium on mortality in long-term treatment of proximal vein thrombosis

Clinical and Applied Thrombosis/Hemostasis

Volumn 2, Issue 1 SUPPL., 1996, Pages

  Hull, Russell D ^a,c   Pineo, Graham F ^a   Brant, Rollin F ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c HSC   (Canada)

Author keywords

Clinical trial; Deep vein thrombosis; Low molecular weight heparin

Indexed keywords

EID: 0005521633     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990;322:1260.
2. Gallus AS, Jackaman J, Tillett J, Mills W, Wycherley A. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986;2:1293.
3. Hull RD, Raskob GE, Rosenbloom D, et al. Optimal therapeutic levels of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992;152:1589.
4. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. Ann Intern Med 1993;119:874.
5. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis. N Engl J Med 1986;315:1109.
6. Hull R, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982;307:1676.
7. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med 1992;326:915.
8. Salzman EW, Deykin D, Shapiro RM, Rosenberg R. Management of heparin therapy: controlled prospective trial. N Engl J Med 1975;292:1046.
9. Wilson JR, Lampman J. Heparin therapy: a randomized prospective study. Am Heart J 1979;97:155.
10. Hull R, Delmore T, Carter C, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982;306:189.
11. Hull R, Delmore T, Genton E, et al. Warfarin sodium versus low dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979;301:855.
12. Dalen JE, Brooks HL, Johnson LW, Meister SG, Szucs MM, Dexter L. Pulmonary angiography in acute pulmonary embolism: indications, techniques, and results in 367 patients. Am Heart J 1971;81:175.
13. Hull RD, Carter CJ, Jay RM, et al. The diagnosis of acute, recurrent, deep-vein thrombosis: a diagnostic challenge. Circulation 1983;67:901.
14. Hull R, Hirsh J, Sackett DL, Powers P, Turpie AG, Walker I. Combined use of leg scanning and impedance plethysmography in suspected venous thrombosis: an alternative to venography. N Engl J Med 1977;296:1497.
15. Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972;104:134.
16. Wheeler HB, O'Donnell JA, Anderson FA Jr, Benedict KJ. Occlusive impedance phlebography: a diagnostic procedure for venous thrombosis and pulmonary embolism. Prog Cardiovasc Dis 1974;17:199.
17. Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972;287:324.
18. Brandjes DPM, Heijboer H, Büller HR, de Rijk M, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992;327:1485.
19. Rooke TW, Osmundson PJ. Heparin and the in-hospital management of deep-venous thrombosis: cost considerations. Mayo Clin Proc 1986;61:198.
20. Hommes DW, Bura A, Mazzolai L, Büller HR, ten Cate JW. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. Ann Intern Med 1992;116:279.
21. Moser KM, Fedullo PF. Subcutaneous compared with intravenous heparin for deep vein thrombosis. Ann Intern Med 1992;117:265.
22. Salzman EW. Low molecular weight heparin. Is small beautiful? N Engl J Med 1986;315:957.
23. Verstraete M. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparin. Drugs 1990;40:498.
24. Bara L, Billaud E, Gramond G, Kher A, Sammama M. Comparative pharmacokinetics of a low molecular weight heparin and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985;39:631.
25. Bergqvist D, Hedner U, Sjorin E, Holmer E. Anticoagulant effects of two types of low molecular weight heparin administered subcutaneously. Thromb Res 1983;32:381.
26. Bratt G, Tornebohm E, Widlund L, Lockner D. Low molecular weight heparin (Kabi 2165; Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 1986;42:613.
27. Frydman AM, Bara L, LeRoux Y, Woler M, Chauliac F, Samama MM. The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol 1988;28:609.
28. Harenberg J, Wurzner B, Zimmermann R, Schettler G. Bioavailability and antagonization of the low molecular weight heparin CY216 in man. Thromb Res 1986;44:549.
29. Matzsch T, Bergqvist D, Hedner U, Ostergaard P. Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers. Thromb Haemost 1987;57:97.
30. Albada J, Neuwenhuis HK, Sixma JJ. Comparison of intravenous standard heparin and Fragmin in the treatment of venous thromboembolism: a randomized double-blind study [Abstract]. Thromb Res 1987;(suppl VI).
31. Arneson KE, Handeland GF, Abildgaard U, Holm HA. What is the optimal dosage of LMW heparin in the subcutaneous treatment of deep vein thrombosis? [Abstract]. Thromb Haemost 1987;58:214.
32. Bratt G, Aberg W, Tornebohm E, Henriksson P, Lockner D. Subcutaneous KABI 2165 in the treatment of deep venous thrombosis of the leg [Abstract]. Thromb Res 1987;7(suppl): 24.
33. Bratt G, Tornebohm E, Granqvist S, Aberg W, Lockner D. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemost 1985;54:813.
34. Holm HA, Ly B, Handeland GF, et al. Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis 1986;16:30.
35. Aiach M, Michaud A, Balian JL, Lefebvre M, Woler M, Fourtillan J. A new low molecular weight heparin derivative, in vitro and in vivo studies. Thromb Res 1983;31:611.
36. Cade JF, Buchanan MR, Boneau B, et al. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation. Thromb Res 1984;35:613.
37. Carter CJ, Kelton JF, Hirsh J, Gent M. Relationship between the antithrombotic and anticoagulant effects of low molecular weight heparin. Thromb Res 1981;21:169.
38. Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982;59:1239.
39. Holmer E, Mattsson C, Nilsson S. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. Thromb Res 1982;25:475.
40. Nurmohamed MT, Rosendaal FR, Buller HR, et al. Low molecular weight heparin in the prophylaxis of venous thrombosis: a meta-analysis. Lancet 1992;340:152.
41. A Collaborative European Multicentre Study. A randomized trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1991;65: 251.
42. Albada J, Nieuwenhuis HK, Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study. Circulation 1989;80:935.
43. Bratt G, Aberg W, Johansson M, Törnebohm E, Granqvist S, Lockner D. Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). Thromb Haemost 1990;64: 506.
44. Handeland GF, Abildgaard U, Holm HA, Arnesen KE. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol 1990;39:107.
45. Harenberg J, Huck K, Bratsch H, et al. Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis. Haemostasis 1990;20(suppl 1):205.
46. Huet Y, Janvier G, Bendriss PH, et al. Treatment of established venous thromboembolism with Enoxaparin: preliminary report. Acta Chir Scand 1990;556(suppl):116.
47. Lockner D, Bratt G, Tornebohm E, Aberg W, Granqvist S. Intravenous and subcutaneous administration of Fragmin in deep venous thrombosis. Haemostasis 1986;16:25.
48. Prandoni P, Vigo M, Cattelan AM, Ruol A. Treatment of deep venous thrombosis by fixed doses of a low-molecular-weight heparin (CY216). Haemostasis 1990;20(suppl 1):220.
49. Siegbahn A, Y-Hassan S, Boberg J, et al. Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-Novo. Thromb Res 1989;55:767.
50. Arnesen H, Heilo A, Jakobson E, Ly B, Skaga E. A prospective study of streptokinase and heparin in the treatment of deep vein thrombosis. Acta Med Scand 1978;203:457.
51. Marder VJ, Soulen RL, Atchartakarn V, et al. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 1977;89:1018.
52. Prandoni P, Leasing AW, Buller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441.
53. Green D, Hull RD, Brant R, Pineo GF. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 1992;339:1476.
54. Hull R, Raskob, Hirsh J, Sackett DL. A cost-effectiveness analysis of alternative approaches for long-term treatment of proximal venous thrombosis. JAMA 1984;252:235.
55. Hull R, Hirsh J, Sackett DL, Stoddart GL. Cost-effectiveness of primary and secondary prevention of fatal pulmonary embolism in high-risk surgical patients. Can Med Assoc J 1982;127: 990.
56. Hull R, Hirsh J, Sackett DL, et al. Cost-effectiveness of clinical diagnosis, venography and non-invasive testing in patients with symptomatic deep-vein thrombosis. N Engl J Med 1981;304: 1561.
57. Hull RD, Feldstein W, Pineo GF, Raskob GE. Cost effectiveness of diagnosis of deep vein thrombosis in symptomatic patients. Thromb Haemost 1995;74:189.